Kauf mal einen Franzosen !!

montag wird es einen zu geben...

für mich synta

de.finance.yahoo.com/q?s=SNTA

Sieht so aus das wir beiden da den Richtigen Riecher gehabt haben :-)

AEterna Zentaris Aktie [WKN: A1J5XC / ISIN: CA0079753038] Denke die Aktie wird noch stark ansteigen!!

globenewswire.com/news-release/2015/01/09/...alth-Canada.html

www.boerse-frankfurt.de/de/aktien/...dr+eo+13+adr+US2683111072

dann schiebt es hier richtig;-)))))

www.nasdaq.com/extended-trading/premarket-mostactive.aspx

Wie wird der Kurs in Amerika?

Weis man vorbörsich was?

Wann wird das Jahresergebnis von 2014 bekanntgegeben? Bzw. die Zahlen zum 4 Quartal?

und kein Interesse hier im Board?

Sehr aufschlussreich!

Interventional Radiology: Guerbet partners HECAM project
12.02.2015 18:02
The HECAM(1) project is a €41 million research and development competitiveness project, financed to the tune of €18.2 million as part of the future investments program(2). Its ambition is to develop detection, diagnosis and treatment tools for hepatocellular carcinoma (HCC), in other words primary liver cancer.

Originally an idea of Claire Corot (Guerbet’s Research & Innovation and Business Development Licensing Director and member of the board of directors of Medicen), the HCC multi-technological approach project was structured by GE Healthcare. Piloted by GE Healthcare, HECAM comprises Guerbet, seven SMEs(3) and three academic partners(4). They provide and develop first-rate scientific and technical competencies within the project.

The benefit of a collaborative approach for a disease with major health consequences such as HCC is huge. And France has excellent academic, structured research, particularly in the field of medical imaging, paving the way for the emergence of innovative solutions.

Click here to read the press release (only in french).


(1) HEpatocellular CArcinoma Multi-technological.

(2) The program is piloted by the French General Investment Commission (CGI) and operated by Bpifrance. Bpifrance, a subsidiary of the Caisse des Dépôts et de l’État, provides loans, guarantees and capital to companies, from their startup to flotation on the stock market.

(3) BioPredictive, CarThera and IntegraGen (Greater Paris Region), BioSIMS Technologies (Upper Normandy), Intrasense (Languedoc-Roussillon), EDAP TMS France and Fluoptics (Rhône-Alpes).

(4) Gustave Roussy, Europe’s leading cancer treatment center, the Paris Public Hospitals Group (with four hospitals: Beaujon, Jean Verdier, Henri Mondor and Paul Brousse) and the French Healthcare and Medical Research Institute (five INSERM units). The consortium is also supported by the Montpellier Regional University Hospital.


www.guerbet.com/our-group/news/2015/news/.../intervention.html  

www.sec.gov/Archives/edgar/data/1041934/...055/newsrelease.htm

Bei den letzten Quartalszahlen ging es im Vorfeld schon nach oben.

www.nasdaq.com/press-release/...lopment-project-20150326-00885

Eigentlich gute Zahlen bis auf die Kosten für die US Zulassung

Rekordumsatz im Jahr 2014 von 26,8 Mio. EUR (35,4 Mio. USD); 11% Wachstum gegenüber dem Vorjahr;
Gesamtjahr HIFU Umsatz stieg 70% gegenüber 2013;
Starke Cash-Position von 12,1 Mio. EUR (14,7 Mio. USD) zum 31. Dezember 2014;
Filing Direkt De-novo-Petition für Ablatherm HIFU pro FDA Diskussionen.

www.nasdaq.com/press-release/...ar-2014-results-20150401-01011

globenewswire.com/news-release/2015/07/07/...-Switzerland.html

globenewswire.com/news-release/2015/11/10/...ago-de-Chile.html

www.nasdaq.com/press-release/...ocal-hifu-trial-20160119-00532
"The publication reports a 100% cancer specific survival at 5 years, a 94% rate of continence preservation and 80% rate of potency preservation."